Drug Trial Radar · NCT03514108
DANHEART (H-HeFT and Met-HeFT)
Last checked: Nov 20, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,100
Actual
Start
Mar 1, 2018
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Henrik WiggersAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Danish Heart Foundation; Danish Council for Independent Research; The Danish Regions: Foundation for Medical Research; Novo Nordisk Foundation; The Aase og Ejnar Danielsen Foundation
- First posted
- May 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present study is testing in a combined design to types of drugs in patients with chronic heart failure: 1) Hydralazine in combination with isosorbide dinitrate (BiDil) and 2) Metformin hydrochloride. The study is double blind, placebo controlled. 1. The first hypothesis is that hydralazine in combination with isosorbide dinitrate can reduce mortality and hospitalization with worsening heart failure in chronic heart failure patients with reduced LVEF. 2. The second hypothesis is that treatment with metformin in chronic heart failure patients with reduced LVEF and type 2 diabetes / diabetes risk / insulin resistance can reduce mortality and cardiovascular hospitalizations. Among secondary endpoints are reduction in new-onset diabetes in heart failure patients with insulin resistance and diabetes risk profile and patient safety.
Conditions
- Heart Failure
- Diabetes
Interventions
Hydralazine Isosorbide DinitrateDrug
Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
Placebo Oral TabletDrug
2 tablets x 3 daily
Metformin HydrochlorideDrug
Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
Placebo Oral TabletDrug
2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
Primary outcomes
What the sponsor says the trial is designed to measure.
- H-HeFT combined primary endpointTime frame: Through study completion, an average of 4 years
- Met-HeFT combined primary endpointTime frame: Through study completion, an average of 4 years
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Sygehus Sønderjylland, Aabenraa
Aabenraa, Denmark
Aalborg University Hospital
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Amager Hospital
Copenhagen, Denmark
Bispebjerg Hospital
Copenhagen, Denmark
Gentofte Hospital
Copenhagen, Denmark
Glostrup Hospital
Copenhagen, Denmark
Herlev Hospital
Copenhagen, Denmark
Hvidovre Hospital
Copenhagen, Denmark
Rigshospitalet
Copenhagen, Denmark
Sydvestjysk Sygehus, Esbjerg
Esbjerg, Denmark
Herning Hospital
Herning, Denmark
Nordsjællands Hospital Hillerød
Hillerød, Denmark
Regionshospital Nordjylland, Hjørring
Hjørring, Denmark
Holbæk Hospital
Holbæk, Denmark
Horsens Hospital
Horsens, Denmark
Kolding Hospital
Kolding, Denmark
Nykøbing Falster Hospital
Nykøbing Falster, Denmark
Odense University Hospital
Odense, Denmark
Randers Hospital
Randers, Denmark
Sjællands Universitetshospital, Roskilde
Roskilde, Denmark
Silkeborg Hospital
Silkeborg, Denmark
Slagelse Sygehus
Slagelse, Denmark
Vejle Hospital
Vejle, Denmark
Viborg Hospital
Viborg, Denmark
Holbæk Hospital
Holbæk, Region Sjælland, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.